Radiglip 50 mg (Tablet)
Unit Price: ৳ 16.00 (2 x 10: ৳ 320.00)
Strip Price: ৳ 160.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sitagliptin |
| Company | Radiant pharmaceuticals ltd |
| Also available as |
Indications
- Adjunct to diet and exercise for glycemic control in type 2 diabetes mellitus
- Not to be used in patients with type 1 diabetes
- Not effective for the treatment of diabetic ketoacidosis
- Not studied in patients with a history of pancreatitis
- Unknown risk for pancreatitis development in patients with a history of pancreatitis
Pharmacology
- DPP-4 inhibitor
- Slows inactivation of incretin hormones
- Increases and prolongs action of incretin hormones
- Increases insulin release and decreases glucagon levels in a glucose-dependent manner
- Increases and prolongs active incretin levels
Dosage & Administration
- Recommended dose of 50 mg twice a day or 100 mg once daily
- Can be taken with or without food
Interaction
- No meaningful alteration of the pharmacokinetics of certain drugs
- Slight increase in mean Digoxin concentration
Contraindications
- History of serious hypersensitivity reaction to sitagliptin
Side Effects
- Common adverse reactions include headache, upper respiratory tract infection, and nasopharyngitis
- Hypoglycemia may occur in patients treated with the combination to Radiglip and sulfonylurea and add on to insulin
Pregnancy & Lactation
- Pregnancy Category B
- Use during pregnancy only if clearly needed
- Caution should be exercised when administered to a nursing woman
Precautions & Warnings
- Prompt discontinuation if pancreatitis is suspected
- Dosage adjustment recommended in patients with moderate or severe renal insufficiency
- Caution required when used with medications known to cause hypoglycemia
- Reports of serious hypersensitivity reactions
- Safety and effectiveness not established in pediatric patients under 18 years
Use in Special Populations
- Not established in pediatric patients under 18 years
- Dosage adjustment in elderly patients with decreased renal function
- Different dosage for patients with mild, moderate, or severe renal insufficiency or end-stage renal disease
Overdose Effects
- Maximal mean increases in QTc of 8.0 msec observed in clinical trials
- Usual supportive measures recommended in the event of an overdose
- Modestly dialyzable
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store below 25°C in a dry place away from light
- Keep out of the reach of children
- Do not use later than the date of expiry
- To be dispensed only on the prescription of a registered physician